Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis C treatment news

Show

From To
Injection drug users with HCV in Scotland lack awareness of DAA efficacy

Most people who inject drugs were not aware of currently available, highly effective hepatitis C treatments, according results of a national survey in Scotland presented at the International Symposium on Hepatitis Care in Substance Users. Researchers asked, “What are the chances of hepatitis C being cured with current treatment?” Most participants responded that the chance was low or less than 40%.

Published
12 September 2017
From
Healio
AbbVie Mavyret Price Threatens Gilead Hepatitis Dominance

AbbVie could have charged a premium for its broader, faster cure. Its choice to go cheap will make Mavyret a huge bargain relative to Gilead's drugs for many patients. Payers will likely seize on that. The major PBMs have purposefully held off on announcing which HCV drugs they'll cover next year. Gilead will have to offer very large discounts or expect to lose market share.

Published
07 August 2017
From
Bloomberg
Direct-acting antivirals successfully treating hepatitis C, says Public Health England

Public Health England (PHE) is urging the public to get tested for hepatitis C after its latest figures revealed a fall in deaths from the disease, which it attributed to the introduction of direct-acting antiviral (DAA) therapy. PHE’s annual report, published on 28 July 2017, estimated that around 200,000 people in the UK are unknowingly living with chronic hepatitis C, but it said that “revolutionary treatments” can successfully treat the disease in the vast majority of cases, with the best results in the earlier stages of the disease.

Published
02 August 2017
From
Pharmaceutical Journal
Australia leads the world in hepatitis C treatment – what's behind its success?

The key to universal access was the Australian government’s capacity to negotiate much lower drug prices than in other high-income countries, following strong advocacy from the hepatitis C sector. For instance, Australia paid an estimated ten-fold lower price per patient treated in 2016 than did Germany.

Published
31 July 2017
From
The Conversation AU
Substantial fall in Hepatitis C rates in Canberra's jail with new treatments

Justice Minister Shane Rattenbury on Friday released new figures showing how new drugs for the virus had helped reduce the number of Hepatitis C-positive inmates from 30% of the prison population in 2010 down to just three per cent this year.

Published
31 July 2017
From
The Canberra Times
Hepatitis C patients unable to get drugs due to funding problems

The treatment of hundreds of patients with hepatitis C with potentially lifesaving drugs has been abruptly halted due to funding problems. The national hepatitis C programme has told hospitals not to make any further applications for funding support for patients until treatment numbers are “realigned”.

Published
31 July 2017
From
Irish Times
From chronic to cured: could Australia be the first country in the world to eliminate hep C?

Australia is on track to eliminate hepatitis C by 2026, a new report released by the Kirby Institute on World Hepatitis Day shows.

Published
28 July 2017
From
Kirby Institute
Australian NSP Survey National Data Report 2012 – 2016

Nationally, the proportion of respondents who reported recent (last 12 months) initiation of HCV treatment was low and stable at 1-3% between 2011-2015, but increased significantly to 22% in 2016, with substantial increases observed in all jurisdictions.

Published
04 July 2017
From
Kirby Institute
Charity calls for new focus to combat Hep C infections in Scotland

A charity has called for greater efforts to eliminate Hepatitis C (HCV) from Scotland. There are about 37,000 people living with the virus - but campaigners say as many again are undiagnosed.

Published
27 June 2017
From
BBC
Swiss hepatitis C sufferers to get full access to expensive drug

The Federal Office of Public Health has announced that it will make the hepatitis C drug Zepatier available to all patients from July 1. The 12-week treatment costs CHF31,000 ($31,952) per patient and was previously only available to those with an advanced form of the disease.

Published
26 June 2017
From
swissinfo.ch
← First12345...66Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.